human von willebrand factor
UkraineDrugs containing this active substance
-
The drug is used for the treatment and prevention of bleeding in patients with hemophilia A (congenital factor VIII deficiency), as well as for the correction of acquired factor VIII deficiency. It is also used for the prevention and treatment of bleeding in von Willebrand disease if desmopressin treatment is ineffective or contraindicated.
Form: lyophilisate for solution for injection
Active substance Dosage human coagulation factor viii 500 IU human von willebrand factor 250 IU ATC: B02BD06
Manufacturer: Biopharma Plazma LLC (manufacturing, primary and secondary packaging, quality control, batch release)
-
The drug is used for the treatment and prevention of bleeding in patients with hemophilia A, as well as for the correction of acquired factor VIII deficiency. It is also used for the prevention and treatment of bleeding in von Willebrand disease if desmopressin is ineffective or contraindicated.
Form: lyophilisate for solution for injection
Active substance Dosage human coagulation factor viii 250 IU human von willebrand factor 125 IU ATC: B02BD06
Manufacturer: Biopharma Plazma LLC (manufacturing, primary and secondary packaging, quality control, batch release)
-
The drug is used for the treatment and prevention of bleeding in patients with hemophilia A, as well as for the correction of acquired factor VIII deficiency. It is also used for the treatment or prevention of bleeding in von Willebrand disease if desmopressin is ineffective or contraindicated.
Form: lyophilisate for solution for injection
Active substance Dosage human coagulation factor viii 1000 IU human von willebrand factor 500 IU ATC: B02BD06
Manufacturer: Biopharma Plazma LLC (manufacturing, primary and secondary packaging, quality control, batch release)
-
The drug is used for the prevention and treatment of bleeding in patients with von Willebrand disease (if other methods are ineffective) and in hemophilia A. It can also be used to control acquired factor VIII deficiency and to treat patients with the presence of antibodies to this factor.
Form: powder and solvent for solution for injection or infusion
Active substance Dosage human blood coagulation factor viii 250 IU or 50 IU/ml human von willebrand factor 600 IU or 120 IU/mL ATC: B02BD06
-
The drug is used for the prevention and treatment of bleeding in von Willebrand disease (if other methods are ineffective) and in hemophilia A. It may also be used to control acquired factor VIII deficiency.
Form: powder and solvent for solution for injection or infusion
Active substance Dosage human blood coagulation factor viii 500 IU or 50 IU/mL human von willebrand factor 1200 IU or 120 IU/ml ATC: B02BD06
-
The drug is used for the prevention and treatment of bleeding in von Willebrand disease (if other methods are ineffective) and in hemophilia A. It can also be used to control acquired factor VIII deficiency and to treat patients with the presence of anti-factor VIII antibodies.
Form: powder and solvent for solution for injection or infusion
Active substance Dosage human blood coagulation factor viii 1000 IU or 66.6 IU/ml human von willebrand factor 2400 IU or 160 IU/ml ATC: B02BD06